Attracting leading experts & the brightest minds in the industry to educate, inform and excite our attendees.

The following are confirmed speakers for Gene Therapy
Development & Manufacturing 2024

Head of Vector Development
Sania Therapeutics
Director in Toxicology
GentiBio
Pharmaceutical CMC Development Manager
Cellectis
Chief Executive Officer
Integra Therapeutics
Senior Director Clinical Operations
Purespring Therapeutics
Head of Gene Therapy
Head of Gene Therapy, Medicine and Healthcare Products Regulatory Agency
Senior Scientist
AstraZeneca
Associate Director Analytical Platforms
uniQure
Senior Director Global Regulatory Affairs
Cellectis
Associate Director, Gene Editing Safety
AstraZeneca
Director of Research
Genethon
Director of Analytical Development
MeiraGTx
Director, Translational Research Office
University College London
Vice President, Head of Analytical Research & Development
Beam Therapeutics
Chief Executive Officer
Genespire
Senior Manager DS/DP MSAT
Orchard Therapeutics
Head of Upstream & Downstream Process Development
Nantes University
Associate Director
Novartis
Group Leader
Wellcome Sanger Institute
Director Cell, Apheresis and Gene Therapies
NHS Blood and Transplant
Senior Scientist
AstraZeneca
Lead Gene Therapy Biophysical Sciences
UCB
Vice President Neurobiology, CNS Sector Lead, Askbio Paris Site Head
Asklepios BioPharmaceutical
Senior Scientist
Hansa Biopharma
Global Medical Director
Novartis Gene Therapies
Value Chain Capability Lead Gene Therapy
Roche
Director, Head Vector Processing
Quell Therapeutics
Head of Vector Biology
UCB
Senior Scientist
UCB
Chief Executive Officer
Coave Therapeutics
Vice President of Gene Therapy Research & Vector Technology
ViGeneron
Quality Analysis Expert
Novartis
Vice President, Strategy and Operations
Resolution Therapeutics
Technical Lead, Gene Therapy
UCB